CirQuest Labs provides highly-efficient drug development programs for the biotech industry that are unique to the product being developed. We bring extensive experience within targeted therapeutic areas that encompass the broad area of life sciences, including, but not limited to, cardiovascular disease and stroke, vascular bed and inflammatory diseases, metabolic syndromes, hematology (including hemostasis and thrombosis), and tumor cell biology. In addition, we can assist you in assessing the biologic effects of medical device or medical implant products for regulatory review, using ISO Standard 10993, Biological Evaluation of Medical Devices, as a minimum standard.
CirQuest Labs offers comprehensive and stand-alone services in preclinical drug development. The goal of our preclinical studies is to determine which drug candidates have the desired mechanism of action and dose-response, and to build a solid scientific rationale for further development that spans all stages of clinical development. We have broad-based expertise in the life sciences. Our team recognizes that you require timely, accurate, and accessible data in order to reach critical decisions that affect the progress of your technology. We are industry leaders in assisting pharmaceutical and device companies of all sizes to make fast and effective product development decisions.